Nascent Australian Firm SpeeDx Seeks Licensees, Partners for 'MNAzyme' Tech

SpeeDx, a spinout of Johnson & Johnson's Australian research subsidiary, claims its multi-component nucleic acid enzymes, or MNAzymes, provide significant advantages over current enzymes for multiplex qPCR applications.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.